Novo Nordisk A/S

Targeted pharmacological therapy restores β-cell function for diabetes remission (2020) Sachs S, Bastidas-Ponce A, Tritschler S, Bakhti M, Boettcher A, Sanchez-Garrido MA, Tarquis-Medina M, et al. Journal article Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials (2020) Mann J, Hansen T, Idorn T, Leiter LA, Marso SP, Rossing P, Seufert J, et al. Journal article Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials (2020) Verma S, Bain SC, Honoré JB, Mann J, A. Nauck M, E. Pratley R, Rasmussen S, et al. Journal article Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial (2020) Mosenzon O, Bain SC, Heerspink HJL, Idorn T, Mann J, Persson F, Pratley RE, et al. Journal article Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER (2019) Perkovic V, Bain SC, Bakris G, Buse JB, Gondolf T, Idorn T, Lausvig N, et al. Conference contribution Impact of microvascular disease on cardiorenal outcomes in type 2 diabetes: an analysis from the LEADER and SUSTAIN 6 clinical trials (2019) Zinman B, Verma S, Bain SC, Honore JB, Mann J, Nauck MA, Pratley R, et al. Conference contribution EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Gondolf T, Idorn T, Lausvig N, et al. Conference contribution Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial" (2019) Mann J, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR Journal article, Note